Evidence map›Paper›PMID 28679845›Full record

ReviewClinical science (London, England : 1979)2017

Negative regulators of angiogenesis: important targets for treatment of exudative AMD.

Mitra Farnoodian, Shoujian Wang, Joel Dietz, Robert W Nickells, Christine M Sorenson, Nader Sheibani

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical science (London, England : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Gene therapy in neovascular age related macular degeneration: an update.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mitra FarnoodianDepartment of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, U.S.A.
Shoujian WangDepartment of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, U.S.A.
Joel DietzDepartment of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, U.S.A.
Robert W NickellsDepartment of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, U.S.A.
Christine M SorensonDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, U.S.A.
Nader SheibaniDepartment of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, U.S.A. nsheibanikar@wisc.edu.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI Donna M Peters · 2005 to 2026
$12.6M
The molecular mechanism of retinal ganglion cell deathR01EY012223 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI NICKELLS, ROBERT W · 2005 to 2017
$6.3M
Novel Antiangiogenic Peptides for Treatment of Exudative AMDR24EY022883 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEIBANI, NADER · 2013 to 2017
$6.2M
Investigating oxygen metabolism in diabetic retinopathyR01EY026078 · NEI · NORTHWESTERN UNIVERSITY · PI SHEIBANI, NADER, ZHANG, HAO F · 2016 to 2020
$2.3M
MOLECULAR MECHANISM OF RETINAL GANGLION CELL DEATHR29EY012223 · NEI · UNIVERSITY OF WISCONSIN MADISON · PI NICKELLS, ROBERT W · 1998 to 2002
$310k
NCI NIH HHS P30 CA014520NEI NIH HHS P30 EY016665NEI NIH HHS R01 EY012223NEI NIH HHS R01 EY026078NEI NIH HHS R24 EY022883NEI NIH HHS R29 EY012223
6 · The paper itself

Abstract

Angiogenesis contributes to the pathogenesis of many diseases including exudative age-related macular degeneration (AMD). It is normally kept in check by a tightly balanced production of pro- and anti-angiogenic factors. The up-regulation of the pro-angiogenic factor, vascular endothelial growth factor (VEGF), is intimately linked to the pathogenesis of exudative AMD, and its antagonism has been effectively targeted for treatment. However, very little is known about potential changes in expression of anti-angiogenic factors and the role they play in choroidal vascular homeostasis and neovascularization associated with AMD. Here, we will discuss the important role of thrombospondins and pigment epithelium-derived factor, two major endogenous inhibitors of angiogenesis, in retinal and choroidal vascular homeostasis and their potential alterations during AMD and choroidal neovascularization (CNV). We will review the cell autonomous function of these proteins in retinal and choroidal vascular cells. We will also discuss the potential targeting of these molecules and use of their mimetic peptides for therapeutic development for exudative AMD.

Indexed as

Angiogenesis InhibitorsAngiostatinsChoroidal NeovascularizationEndostatinsEye ProteinsHumansMacular DegenerationMolecular Targeted TherapyNerve Growth FactorsPigment Epithelium-Derived FactorSerpinsThrombospondinsAngiogenesis InhibitorsAngiostatinsEndostatinsEye ProteinsNerve Growth FactorsPigment Epithelium-Derived FactorSerpinsThrombospondinsangiogenesisendothelial cellsPEDFpericytesretinal pigment epithelial cellsthrombospondins

Identifiers

PMID28679845
PMCPMC6016847
OpenAlexW2734136842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.